Chapter 13 – Vasospasm

[1]  G. Murray,et al.  Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial , 2014, The Lancet Neurology.

[2]  A. Algra,et al.  Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial , 2012, The Lancet.

[3]  Paul Vespa,et al.  Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2012, Stroke.

[4]  S. Mayer,et al.  Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling , 2012, Stroke.

[5]  Z. Wang,et al.  Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage , 2012, European Journal of Clinical Pharmacology.

[6]  K. Hoffmann,et al.  The use of nicardipine prolonged release implants (NPRI) in microsurgical clipping after aneurysmal subarachnoid haemorrhage: comparison with endovascular treatment , 2011, Acta Neurochirurgica.

[7]  B. Hoh,et al.  Critical Care Guidelines on the Endovascular Management of Cerebral Vasospasm , 2011, Neurocritical care.

[8]  S. Mayer,et al.  Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2) , 2011, The Lancet Neurology.

[9]  I. C. Schaaf,et al.  Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review , 2010, Critical care.

[10]  J. Pickard,et al.  Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. , 2009, Journal of neurosurgery.

[11]  Jan Claassen,et al.  Defining Vasospasm After Subarachnoid Hemorrhage: What Is the Most Clinically Relevant Definition? , 2009, Stroke.

[12]  P. Vajkoczy,et al.  Characterization of functional outcome and quality of life following subarachnoid hemorrhage in patients treated with and without nicardipine prolonged-release implants. , 2009, Journal of neurosurgery.

[13]  S. Mayer,et al.  Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1): Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial , 2008, Stroke.

[14]  M. Lauritzen,et al.  Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. , 2006, Brain : a journal of neurology.

[15]  W. Poon,et al.  Intravenous Magnesium Sulfate After Aneurysmal Subarachnoid Hemorrhage: A Prospective Randomized Pilot Study , 2006, Journal of neurosurgical anesthesiology.

[16]  W. M. Bergh.  Magnesium Sulfate in Aneurysmal Subarachnoid Hemorrhage A Randomized Controlled Trial , 2005 .

[17]  G. Murray,et al.  Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. , 1989, BMJ.

[18]  W. Couldwell,et al.  Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage , 2005, Neurocritical care.